Cargando…

Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer

There is an urgent need for exploring new actionable targets other than androgen receptor to improve outcome from lethal castration-resistant prostate cancer. Tumor metabolism has reemerged as a hallmark of cancer that drives and supports oncogenesis. In this regard, it is important to understand th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Stephen Y. C., Ribeiro, Caroline Fidalgo, Wang, Yuzhuo, Loda, Massimo, Plymate, Stephen R., Uo, Takuma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687810/ https://www.ncbi.nlm.nih.gov/pubmed/36358940 http://dx.doi.org/10.3390/biom12111590

Ejemplares similares

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
por: Zadra, Giorgia, et al.
Publicado: (2019)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand
por: Liu, Gang, et al.
Publicado: (2014)

Castration-resistant prostate cancer cells are dependent on the high activity of CDK7
por: Pallasaho, Satu, et al.
Publicado: (2022)

The PHLPP2 phosphatase is a druggable driver of prostate cancer progression
por: Nowak, Dawid G., et al.
Publicado: (2019)

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer
por: Bae, Song Yi, et al.
Publicado: (2023)

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
por: Seguin, Laetitia, et al.
Publicado: (2018)

Polycomb-independent activity of EZH2 in castration resistant prostate cancer
por: Xu, Kexin, et al.
Publicado: (2013)

ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development
por: He, Haiqing, et al.
Publicado: (2021)

Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking
por: Brew, Tom, et al.
Publicado: (2021)

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016)

RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition
por: Han, Wanting, et al.
Publicado: (2022)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
por: Sureka, Sanjoy Kumar, et al.
Publicado: (2016)

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
por: Watahiki, Akira, et al.
Publicado: (2013)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
por: Yin, Lina, et al.
Publicado: (2013)

Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes
por: Plymate, Stephen R., et al.
Publicado: (2022)

Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain
por: Uo, T, et al.
Publicado: (2017)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer
por: Samaranayake, Govindi J., et al.
Publicado: (2017)

Distinct mesenchymal cell states mediate prostate cancer progression
por: Pakula, Hubert, et al.
Publicado: (2023)

HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
por: Koeneke, Emily, et al.
Publicado: (2015)

Chemoproteomics of an Indole-Based Quinone Epoxide Identifies Druggable Vulnerabilities in Vancomycin-Resistant Staphylococcus aureus
por: Kulkarni, Amogh, et al.
Publicado: (2019)

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)

An update on TroVax(®) for the treatment of progressive castration-resistant prostate cancer
por: Abern, Michael, et al.
Publicado: (2011)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
por: Gunter, Jennifer H., et al.
Publicado: (2012)

20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer
por: Cao, Bo, et al.
Publicado: (2014)

Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
por: Wang, Keshan, et al.
Publicado: (2018)

Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer
por: Ye, Chen, et al.
Publicado: (2019)

The cost impact of disease progression to metastatic castration-sensitive prostate cancer
por: Trinh, Quoc-Dien, et al.
Publicado: (2022)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR
por: Rojas, Andres, et al.
Publicado: (2011)

When fat goes down, prostate cancer is on the ropes
por: Zadra, Giorgia, et al.
Publicado: (2019)

An RNA Interference Lethality Screen of the Human Druggable Genome to Identify Molecular Vulnerabilities in Epithelial Ovarian Cancer
por: Sethi, Geetika, et al.
Publicado: (2012)

mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
por: Gremke, Niklas, et al.
Publicado: (2020)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Cannot write session to /tmp/vufind_sessions/sess_j1filqklduodmj3d1ad69b7h2c